Cambridge Healthtech Institute’s 5th Annual

Oncolytic Virus Immunotherapy

Engineering, Developing and Commercializing Oncolytic Virotherapy

August 10-11, 2020

The use of oncolytic viruses has expanded rapidly over the past five years with interest in the field at an all-time high following recent scientific breakthroughs and multi-million dollar investments from big pharma. Cambridge Healthtech Institute’s Fifth Annual Oncolytic Virus Immunotherapy conference brings together leading academics, clinicians and industry experts to discuss the latest developments in oncolytic virotherapy and the steps needed to accelerate product development – from virus engineering to new mechanisms of action; combinations to major clinical updates; delivery to commercialization.

Preliminary Agenda


KEYNOTE PRESENTATION: Recombinant Poliovirus for Cancer Immunotherapy

Matthias Gromeier, MD, Professor, Department of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke Cancer Institute, Duke University Medical School

Lessons Learned from Preclinical and Clinical Development of Retroviral Replicating Vectors

Noriyuki Kasahara, MD, PhD, Alvera L. Kan Endowed Chair, Professor in Residence, Departments of Neurological Surgery and Radiation Oncology, UCSF


Targeting Tumor Escape with Mechanism-Based Oncolytic Viroimmunotherapy

Richard Vile, PhD, Professor, Immunology, Mayo Clinic

Rational Design of Oncolytic Viruses for Cancer Immunotherapy

Liang Deng, MD, PhD, Associate Member, Program Director, Dermatology Service, Department of Medicine, Head, Memorial Hospital Laboratory

Development of Tumor-Localized Immunogene Therapy Approaches for the Treatment of Carcinomas

Brian R. Champion, PhD, CSO, PsiOxus Therapeutics Ltd.

Integrating Oncolytic Viruses into Combination Therapy for Cancer

Howard L. Kaufman, MD, Head of R&D, Immuneering Corp

Combination with Oncolytic Adeno-Immunotherapy and CAR T Cell for Advanced Solid Tumors

Masataka Suzuki, PhD, Assistant Professor, Center for Cell & Gene Therapy, Department of Medicine, Baylor College of Medicine

Oncolytic HSV Combinations; Sometimes They Work

Samuel D. Rabkin, PhD, Professor of Neurosurgery, Massachusetts General Hospital and Harvard Medical School

Next-Generation Oncolytic Immuno-Gene Therapy Based on HSV

Rob Coffin, PhD, CEO, RepLimmune

Impact of Oncolytic HSV on NOTCH Signaling

Balveen Kaur, PhD, Professor; Vice Chair Research; John P. and Kathrine G. McGovern Endowed Chair, Department of Neurosurgery, University of Texas

Development of RIVAL-01, a Novel Oncolytic Vaccinia Virus Expressing Immunomodulatory Therapeutic Transgenes

Caroline Breitbach, PhD, Vice President, Translational Science, Turnstone

* The program is subject to change without notice, due to unforeseen reason.

Choose your language